Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
    Journal Article

    Issa, G. C.; Aldoss, I.; DiPersio, J.; Cuglievan, B.; Stone, R.; Arellano, M.; Thirman, M. J.; Patel, M. R.; Dickens, D. S.; Shenoy, S.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • MEN1 mutations mediate clinical resistance to menin inhibition
    Journal Article

    Perner, F.; Stein, E. M.; Wenge, D. V.; Singh, S.; Kim, J.; Apazidis, A.; Rahnamoun, H.; Anand, D.; Marinaccio, C.; Hatton, C.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
    Journal Article

    Bewersdorf, J. P.; Patel, K. K.; Goshua, G.; Shallis, R. M.; Podoltsev, N. A.; Stahl, M.; Stein, E. M.; Huntington, S. F.; Zeidan, A. M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
    Journal Article

    Bewersdorf, J. P.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer
    Journal Article

    Petrone, G.; Gaulin, C.; Derkach, A.; Kishtagari, A.; Robson, M. E.; Parameswaran, R.; Stein, E. M.
    Haematologica (2023)

    Fulltext@MSK | Save
  • IDH2 inhibition in AML
    Editorial

    Stein, E. M.
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Journal Article

    Stahl, M.; Derkach, A.; Farnoud, N.; Bewersdorf, J. P.; Robinson, T.; Famulare, C.; Cho, C.; Devlin, S.; Menghrajani, K.; Patel, M. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Outcomes based on sequential use of venetoclax based therapy and targeted therapy in acute myeloid leukemia (AML)
    Meeting Abstract

    Stahl, M.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • SELECT-AML-1 trial in progress: A phase 2 study of tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy
    Meeting Abstract

    Kambhampati, S.; Eghtedar, A.; McMahon, C.; de Botton, S.; Pigneux, A.; Ball, B.; Borthakur, G.; Angela, V.; Gausman, J. A.; Baker, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Trial in progress: Phase Ib/II study of siremadlin in combination with venetoclax plus azacitidine in patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy (IC)
    Meeting Abstract

    Daver, N. G.; Wei, A. H.; Stein, E. M.; DeAngelo, D. J.; Pathak, D.; Xu, Y. N.; Grzesiak, S.; Venditti, A.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save